CGH Medical Center

Recent papers from CGH Medical Center

1. Does the evidence support the ACC/AHA Multisociety Recommendation to measure apoB only after LDL-C and non-HDL-C are at target?Journal of clinical lipidology · 2026
2. Profound reductions in first and total cardiovascular events with icosapent ethyl in the REDUCE-IT trial: why these results usher in a new era in dyslipidaemia therapeuticsEuropean Heart Journal · 2019
3. Friedewald-Estimated Versus Directly Measured Low-Density Lipoprotein Cholesterol and Treatment ImplicationsJournal of the American College of Cardiology · 2013
4. Triglyceride-lowering therapies for hepatic steatosis: mechanisms, efficacy, and clinical perspectivesFrontiers in Pharmacology · 2026
5. Hepatic Sensing Loop Regulates PCSK9 Secretion in Response to Inhibitory AntibodiesJournal of the American College of Cardiology · 2021
6. Eliminating atherosclerotic cardiovascular disease residual riskEuropean Heart Journal · 2023
7. Lipoprotein subfractions and coronary artery calcium progression: insights from the Brazilian Longitudinal Study of Adult Health (ELSA-Brasil)European Journal of Preventive Cardiology · 2026
8. Targeting Triglycerides in Cardiovascular Disease Prevention: Evidence, Mechanisms, and Emerging TherapiesCurrent Cardiology Reports · 2026
9. 2025: The year in cardiovascular disease – the year of triglyceride lowering therapies. Can we effectively reduce triglyceride-related residual cardiovascular disease and pancreatitis risk?SHILAP Revista de lepidopterología · 2025
10. The Metabolic Vulnerability Index (MVX) in Subclinical Thyroid Disorders and Euthyroidism: A Cross-Sectional Exploratory Analysis from the ELSA-Brasil StudyMetabolites · 2025
11. High-Density Lipoproteins. Part 2. Impact of Disease States on FunctionalityAmerican Journal of Preventive Cardiology · 2025
12. High-density lipoproteins, Part 1. Epidemiology, antiatherogenic effects, and therapies designed to increase their serum levelsAmerican Journal of Preventive Cardiology · 2025
13. Despite more aggressive lipid-lowering guidelines worldwide, the majority of high-risk patients remain undertreatedEuropean Journal of Preventive Cardiology · 2025
14. Plasma Levels of Small HDL Particles Are Associated With Coronary Atherosclerosis Progression in Adults With DiabetesThe Journal of Clinical Endocrinology & Metabolism · 2025
15. Low-density lipoprotein-cholesterol subfractions as predictors for coronary artery calcium incidence and progression – The Brazilian longitudinal study of Adult Health (ELSA – Brasil)Atherosclerosis · 2025
16. Cross-Sectional analysis of demographic and clinical characteristics of patients in the United States using icosapent ethylFrontiers in Cardiovascular Medicine · 2025
17. Association of obesity and LDL subfractions evaluated by body mass index, waist circumference, and diabetes status: the ELSA-Brasil studyDiabetology & Metabolic Syndrome · 2025
18. 2024: The Year in Cardiovascular Disease - The Year of Lipoprotein(a) – Research Advances and New Findings.Archives of Medical Science · 2025
19. Management of children with heterozygous familial hypercholesterolaemia worldwide: a meta-analysisEuropean Heart Journal Open · 2024
20. Hemoglobin A1c and abdominal obesity as predictors of diabetes and ASCVD in individuals with prediabetes in UK Biobank: a prospective observational studyCardiovascular Diabetology · 2024